N-乙酰半胱氨酸联合沙美特罗治疗慢性阻塞性肺疾病临床研究

Clinical study of N-acetylcysteine combined with salmeterol in the treatment of chronic obstructive pulmonary disease

目的探讨N-乙酰半胱氨酸联合沙美特罗治疗慢性阻塞性肺疾病的临床效果。方法回顾性分析2014年8月至2016年2月106例慢性阻塞性肺疾病患者的临床资料。结果治疗组总有效率为90.57%,治疗后第1秒用力肺活量(FEV_1)为(1.89±0.42)L,FEV_1占预计值比值为(88.63±12.47)%,FEV_1/用力肺活量(FVC)为(81.92±11.33)%,动脉血氧分压(PaO_2)为(78.15±7.36)mmHg(1 mmHg=0.133 k Pa),动脉血二氧化碳分压(PaCO_2)为(34.63±3.88)mmHg,均优于对照组,差异均有统计学意义(P<0.05)。结论 N-乙酰半胱氨酸联合沙美特罗治疗慢性阻塞性肺疾病的临床效果显著,具有临床推广价值。

Objective To investigate the clinical effect of N-acetylcysteine combined with salmeterol on chronic obstructive pulmonary disease.Methods The clinical data of 106 patients with chronic obstructive pulmonary disease from August 2014 to February 2016 were retrospectively analyzed.Results The total effective rate of the treatment group and the control group was 90.57% and 73.58% respectively, there was significant difference （P〈0.05）.After treatment, the FEV1 of the treatment group was （1.89±0.42） L, the proportion of FEV1 was （88.63±12.47）%, FEV1/FVC was （81.92±11.33）%, PaO2 was （78.15±7.36） mmHg（1 mmHg=0.133 kPa）, PaCO2 was （34.63±3.88） mmHg, which were better than those of the control group, the differences were significant （P〈0.05）.Conclusion N-acetylcysteine combined with salmeterol has significant clinical value on chronic obstructive pulmonary disease.